EUCTR2004-002965-19-SE进行中（未招募）不适用
Can risedronate prevent periprosthetic bone loss after hip arthroplasty?A randomized, double-blind, placebo-controlled trial - PREVENT
Orthopaedic department, Karolinska Institutet, Danderyd's Hospital0 个研究点开始时间: 2005年2月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients waiting for total hip arthroplasty due to primary or secondary osteoarthritis of the hip.
- •Patients between 40-70 years of age.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with rhematoid arthritis or earlier infection of the hip
- •Steroid treatment
- •Bisphosphonate treatment
- •Osteomalacia
- •Hypocalcemia
研究者
相似试验
已完成
4 期
Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip ArthroplastyBone LossNCT00772395Danderyd Hospital78
已完成
4 期
The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid TreatmentOsteoporosisNCT00372372Tuen Mun Hospital120
进行中（未招募）
不适用
Effects of generic risedronate on bone turnover markers and bone mineral density in Thai postmenopausal osteoporosis.postmenopausal womenBone turnover markersrisedronateBMDosteoporosisTCTR20240427002Ratchadapisek Research Funds80
已完成
2 期
Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of BoneFibrous Dysplasia of BoneNCT00445575Institut National de la Santé Et de la Recherche Médicale, France80
已完成
3 期
Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.Acute Spinal Cord Injury.NCT00150696Toronto Rehabilitation Institute38